After backlash from patients, CVS restores coverage of popular weight-loss drug Zepbound

CVS Caremark , one of America’s most powerful pharmacy benefit managers, will begin covering more GLP-1 medications again later this year, potentially expanding access to the blockbuster weight-loss drug for millions of Americans.

After backlash from patients, CVS restores coverage of popular weight-loss drug Zepbound. CVS Caremark , one of America’s most powerful pharmacy benefit managers, will begin covering more GLP-1 medications again later this year, potentially expanding access to the blockbuster weight-loss drug for millions of Americans. CVS announced Thursday that it would restore Eli Lilly’s weight-loss injection Zepbound to its list of covered drugs on Caremark’s standard commercial formulary template, which represents roughly 25 million to 30 million Americans, CVS spokesman Philip Blando told the Globe. Caremark will also add the drugmaker’s newly approved oral obesity pill, Foundayo. Pharmacy benefit managers play a key role negotiating drug prices, processing pharmacy claims, handling prescription authorizations, and managing drug benefits for health...